

Hideaki Bando

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/19789/publications.pdf>

Version: 2024-02-01

41
papers

1,262
citations

361413

20
h-index

395702

33
g-index

41
all docs

41
docs citations

41
times ranked

1741
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I study of the irreversible fibroblast growth factor receptor 1â€“4 inhibitor futibatinib in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2023, 114, 574-585.	3.9	13
2	Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2022, 21, 3-9.	2.3	11
3	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€“High Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1136-1146.	7.0	62
4	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. <i>JCO Precision Oncology</i> , 2022, 6, e2100383.	3.0	8
5	Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Antiâ€“PD-1 Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 2110-2117.	7.0	30
6	Rapid Screening Using Pathomorphologic Interpretation to Detect <i>BRF1</i> Mutation and Microsatellite Instability in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2623-2632.	7.0	4
7	Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100535.	3.0	29
8	Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1413-1420.	2.2	2
9	The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data. <i>Future Oncology</i> , 2022, 18, 2709-2721.	2.4	3
10	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. <i>Clinical Cancer Research</i> , 2022, 28, 3480-3488.	7.0	8
11	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <i>RAS</i> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , 2021, 27, 2515-2522.	7.0	39
12	Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a firstâ€“line treatment for metastatic colorectal cancer: Safety leadâ€“in results from the QUATTRO-II study. <i>Investigational New Drugs</i> , 2021, 39, 1649-1655.	2.6	3
13	REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 674.	2.6	19
14	Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA. <i>Cancer Science</i> , 2021, 112, 3911-3917.	3.9	17
15	Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5619-5627.	7.0	27
16	SCRUMâ€“Japan GIâ€“SCREEN and MONSTARâ€“SCREEN: Path to the realization of biomarkerâ€“guided precision oncology in advanced solid tumors. <i>Cancer Science</i> , 2021, 112, 4425-4432.	3.9	24
17	Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis. <i>Cancer Medicine</i> , 2020, 9, 394-400.	2.8	12
18	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. <i>Nature Medicine</i> , 2020, 26, 1859-1864.	30.7	209

#	ARTICLE	IF	CITATIONS
19	Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer, 2020, 20, 687.	2.6	9
20	Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition. Cancer Science, 2020, 111, 3962-3969.	3.9	18
21	BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. ESMO Open, 2020, 5, e000624.	4.5	15
22	Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.. Journal of Clinical Oncology, 2020, 38, 4100-4100.	1.6	40
23	Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. Cancer Science, 2019, 110, 3049-3060.	3.9	20
24	A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. British Journal of Cancer, 2019, 120, 982-986.	6.4	64
25	Phase I dose-escalation study of capmatinib (<sc>INC</sc>280) in Japanese patients with advanced solid tumors. Cancer Science, 2019, 110, 1340-1351.	3.9	33
26	Precision Oncology and the Universal Health Coverage System in Japan. JCO Precision Oncology, 2019, 3, 1-12.	3.0	39
27	Response to Anti-EGFR Therapy in Patients with BRAF non-V600E Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 7089-7097.	7.0	79
28	TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by circulating tumor DNA.. Journal of Clinical Oncology, 2019, 37, TPS3156-TPS3156.	1.6	2
29	A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. Clinical Colorectal Cancer, 2018, 17, 147-155.	2.3	35
30	Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene, 2018, 37, 1775-1787.	5.9	28
31	Utility of the quasi-monomorphic variation range in unresectable metastatic colorectal cancer patients. Cancer Science, 2018, 109, 3411-3415.	3.9	35
32	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition) Tj ETQq0 0.0 rgBT /Overlock 10	3.9	38
33	The current status and problems confronted in delivering precision medicine in Japan and Europe. Current Problems in Cancer, 2017, 41, 166-175.	2.0	17
34	Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials. Gastric Cancer, 2017, 20, 481-488.	5.3	3
35	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. British Journal of Cancer, 2017, 117, 1450-1458.	6.4	52
36	Clinical utility of quasimonomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in Japanese patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01.. Journal of Clinical Oncology, 2017, 35, TPS808-TPS808.	1.6	1

#	ARTICLE	IF	CITATIONS
37	A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). <i>European Journal of Cancer</i> , 2016, 62, 46-53.	2.8	40
38	Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 919-926.	5.3	36
39	Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. <i>Investigational New Drugs</i> , 2015, 33, 664-670.	2.6	3
40	A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 258.	2.6	93
41	Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. <i>BMC Cancer</i> , 2013, 13, 405.	2.6	42